Curtis L. Scribner

Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Symphony Allegro, Inc. manufactures biopharmaceutical drugs. It develops clinical trials for the treatment of schizophrenia, bipolar, migraine, and panic attack disorders. The company was founded in 2006 and is headquartered in Rockville, MD.

IQVIA RDS Consulting, Inc. provides global regulatory, compliance, and validation consulting services. The company offers strategic regulatory consulting in the areas of quality systems development and optimization, FDA enforcement solutions, validation, and bioresearch monitoring. It provides services to the pharmaceutical, biotechnology, and medical device industries. The company was founded in 2001 and is located in Vernon Hills, IL.

RRD International LLC develops biopharmaceutical products. The firm offers product development support to biotechnology, pharmaceutical and medical device companies. Its services include development, strategic planning, program management and research. The company was founded by Frank L. Hurley and Charles W. Finn in 2002 and is headquartered in Rockville, MD.

Flightpath Biosciences, Inc. operates as a biotechnology company. The firm develops novel therapeutics for the treatment of tick-borne diseases and acute and post treatment Lyme disease. The company was founded by Mark de Souza, Matthew Tindall, and Curtis Scribner in 2019 and is headquartered in Berkeley, CA.